Understanding the scientific evidence connecting substance use with fertility, early fetal development, pregnancy complications, and the importance of personalized preconception care for both prospective parents.
Pregnancy does not begin biologically at the first prenatal appointment.
By the time someone receives a positive pregnancy test, several important developmental events may already be underway.
Fertilization has occurred, early embryonic cells have begun dividing, and the biological processes responsible for implantation and subsequent development are progressing.
In the following weeks, the foundations of major organ systems begin to form.
Consequently, exposures occurring before pregnancy recognition may overlap with sensitive periods of development.
This creates an important opportunity for preventive healthcare.
Preconception care allows individuals and couples to evaluate potentially harmful exposures, address modifiable risks, and establish appropriate support before pregnancy begins.
Among the exposures worth discussing are alcohol, tobacco and nicotine products, cannabis, nonmedical substance use, and prescription medications that require individualized review.
These substances differ considerably in their pharmacology, potential effects, and appropriate management.
They should not be treated as interchangeable.
Nevertheless, they share one important characteristic: understanding patterns of exposure before conception can help clinicians and prospective parents make more informed decisions.
A foundational 2008 publication in the American Journal of Obstetrics & Gynecology, titled The Clinical Content of Preconception Care: Alcohol, Tobacco, and Illicit Drug Exposures, emphasized this principle.
Floyd and colleagues argued that screening and early intervention should be incorporated into routine care for individuals planning pregnancy or capable of becoming pregnant.
Since then, research published in JAMA, The New England Journal of Medicine, and Nature Portfolio journals has expanded our understanding of prenatal substance exposure, reproductive health, and the value of evidence-based treatment.
The contemporary evidence also reinforces an important distinction.
Avoiding unnecessary exposure is often the appropriate goal.
However, treating an established substance use disorder requires compassionate, individualized healthcare—not simply telling someone to stop.
1. Why Preconception Health Matters Before the First Prenatal Visit
Preconception care refers to healthcare provided before pregnancy to identify and address factors that may influence fertility, pregnancy outcomes, and the health of prospective parents.
It can include nutritional assessment, medication review, management of chronic conditions, vaccination history, reproductive planning, and discussion of lifestyle-related exposures.
The American College of Obstetricians and Gynecologists and the American Society for Reproductive Medicine recommend incorporating preconception counseling into routine healthcare encounters.
Their guidance includes asking about alcohol, nicotine, drug use, prescription medications, and other relevant exposures.
Why is timing important?
Some developmental events occur before a person realizes they are pregnant.
For example, neural tube closure generally occurs approximately four weeks after fertilization, around six weeks of gestational age when calculated from the last menstrual period.
This is one reason appropriate folic acid supplementation is recommended before conception rather than waiting until pregnancy is confirmed.
The same timing consideration applies to potentially harmful exposures.
A person may not recognize pregnancy until several weeks after conception.
Consequently, discussing alcohol and other substances before pregnancy can reduce the likelihood of exposure during early development.
However, this does not mean every exposure before pregnancy recognition causes harm.
Risk depends on the substance, dose, timing, duration, and other factors.
A history of exposure should prompt an informed discussion rather than assumptions about pregnancy outcomes.
2. Understanding the Reproductive Exposome
The exposome describes the totality of environmental exposures experienced throughout life and their interactions with biological systems.
For reproductive health, relevant exposures may occur before conception, during pregnancy, and after birth.
These include nutritional conditions, medications, environmental chemicals, infections, alcohol, tobacco, and other substances.
Their biological effects may involve endocrine regulation, cellular signaling, metabolism, oxidative stress, or other pathways.
Some exposures are known to cause developmental harm.
Others are associated with certain outcomes without definitive evidence of causation.
Still others remain insufficiently studied.
This distinction is especially important when discussing fertility and child development.
An exposure can influence biological pathways without necessarily producing a clinically meaningful outcome.
Similarly, identifying a molecular change does not prove that it will result in a developmental disorder.
An evidence-informed preconception approach therefore prioritizes exposures with established or plausible risks and interventions supported by clinical evidence.
3. Alcohol: Why Preconception Counseling Is Important
Alcohol is a well-established developmental toxicant.
During pregnancy, alcohol can cross the placenta and expose the developing embryo or fetus.
Prenatal alcohol exposure is associated with a spectrum of potential developmental outcomes, including fetal alcohol spectrum disorders, or FASD.
These conditions may involve differences in growth, neurodevelopment, learning, executive function, attention, and behavior.
The severity and presentation vary considerably.
Importantly, not every pregnancy exposed to alcohol results in FASD.
However, no amount of alcohol consumption during pregnancy has been established as safe.
For this reason, the CDC and major obstetric organizations recommend avoiding alcohol during pregnancy and when attempting to conceive.
This recommendation is based on avoiding preventable exposure during periods when pregnancy may not yet be recognized.
It does not imply that every isolated drink causes injury.
4. What Does the Research Say About Fetal Alcohol Spectrum Disorders?
The original 2008 AJOG paper recognized alcohol exposure as an important preventable contributor to developmental disability.
Subsequent research has improved estimates of the frequency of FASD.
A major 2018 study published in JAMA, Prevalence of Fetal Alcohol Spectrum Disorders in 4 US Communities, evaluated first-grade children across four geographically distinct communities.
The researchers identified 222 cases among 6,639 children selected for assessment.
Conservative prevalence estimates ranged from approximately 1.1% to 5.0% across the study communities.
These findings suggested that fetal alcohol spectrum disorders may be more common than older estimates indicated.
However, the study was not designed to establish one nationally representative prevalence figure.
Its broader importance was demonstrating that some affected children may remain unrecognized when researchers rely exclusively on existing medical diagnoses.
This reinforces the value of prevention and appropriate developmental assessment.
5. Alcohol Exposure and the Developing Nervous System
Alcohol can affect several developmental processes, including neuronal proliferation, migration, differentiation, and cellular survival.
Its effects are influenced by the developmental stage during which exposure occurs.
The nervous system develops throughout pregnancy.
Consequently, alcohol-related developmental risk is not limited to one early period.
Recent research continues to investigate these relationships.
A 2025 JAMA Network Open study, Prenatal Tobacco and Alcohol Exposure and Cortical Change Among Youths, evaluated longitudinal brain imaging among more than 5,000 children.
The researchers found that prenatal tobacco exposure was associated with differences in cortical thinning trajectories during early adolescence.
In contrast, prenatal alcohol exposure was not significantly associated with the cortical measurements examined in that study.
This finding does not overturn the established evidence concerning alcohol-related developmental harm.
The investigation assessed particular brain-imaging outcomes over a limited period, rather than every potential effect of prenatal alcohol exposure.
It illustrates why individual studies must be interpreted according to their specific methods and measured outcomes.
6. What If Someone Drank Alcohol Before Realizing They Were Pregnant?
This is a common concern.
A person may consume alcohol before receiving a positive pregnancy test and worry about the potential effects.
The appropriate response is not to assume that harm has occurred.
Alcohol-related developmental risks depend on several factors, including the amount consumed, pattern of consumption, and timing of exposure.
However, because a safe threshold has not been established, stopping alcohol consumption once pregnancy is recognized is recommended.
The next step is to discuss the exposure with an obstetric healthcare professional.
Accurate information about timing and approximate quantity may help guide counseling.
Patients should not be shamed for exposures that occurred before pregnancy recognition.
Nor should they be given unsupported assurances that a particular exposure was completely harmless.
The goal is individualized assessment, appropriate prenatal care, and informed decision-making.
7. Screening and Brief Counseling: Does It Actually Work?
The original AJOG paper emphasized the importance of identifying unhealthy alcohol use before pregnancy.
This remains supported by later research.
In 2018, the U.S. Preventive Services Task Force published an updated recommendation in JAMA supporting screening for unhealthy alcohol use among adults, including pregnant individuals.
The recommendation also supports brief behavioral counseling when unhealthy drinking is identified.
The associated evidence review found that counseling interventions can reduce unhealthy alcohol consumption.
Benefits included reductions in heavy drinking episodes and the frequency of exceeding recommended limits.
For pregnant individuals, limited available evidence suggested that counseling can improve the likelihood of abstaining from alcohol.
This is important because effective preconception care involves more than identifying potential risk.
It also involves providing a practical pathway toward change.
For individuals with alcohol dependence, specialized treatment may be necessary.
Abrupt cessation in a person at risk for severe alcohol withdrawal can be medically dangerous and warrants prompt clinical assessment.
8. Tobacco Exposure: Established Risks for Fertility and Pregnancy
Cigarette smoking is associated with several adverse reproductive and pregnancy outcomes.
These include reduced fertility, ectopic pregnancy, miscarriage, impaired fetal growth, preterm birth, placental complications, and stillbirth.
Smoking during pregnancy is also associated with increased risk of sudden infant death syndrome and respiratory problems in offspring.
These associations are supported by extensive epidemiological and clinical research.
Tobacco smoke contains numerous biologically active compounds.
Nicotine influences cardiovascular and neurobiological signaling.
Combustion produces carbon monoxide and other toxic substances.
Carbon monoxide can impair oxygen transport, while other smoke constituents contribute to vascular dysfunction and cellular injury.
The developing placenta and fetus are particularly relevant to these effects.
Smoking cessation before pregnancy is therefore an important preventive objective.
However, cessation at any point during pregnancy can still provide meaningful benefits.
9. What About Vaping and Other Nicotine Products?
Modern nicotine exposure differs considerably from the tobacco landscape described in 2008.
Electronic cigarettes, nicotine pouches, and other products have become increasingly common.
These products should not be considered equivalent to combustible cigarettes in their chemical exposure profiles.
For example, an electronic cigarette does not generate the same combustion products as a traditional cigarette.
However, this distinction does not establish that vaping is safe during pregnancy.
Nicotine itself can affect cardiovascular and developmental signaling.
Electronic cigarette aerosols may also contain other substances depending on device characteristics and product formulation.
In 2021, the USPSTF published tobacco-cessation recommendations in JAMA addressing adults, including pregnant individuals.
The Task Force concluded that behavioral interventions provide substantial benefits for smoking cessation during pregnancy.
However, it found insufficient evidence to determine the overall balance of benefits and harms associated with electronic cigarettes as cessation tools.
Similarly, evidence concerning tobacco-cessation medications during pregnancy remains more limited than in nonpregnant adults.
The appropriate preconception goal is to discontinue tobacco and unnecessary nicotine exposure with evidence-based support.
For individuals who require additional treatment, medication decisions should be individualized with qualified healthcare professionals.
10. Why Quitting Before Conception Can Be More Effective Than Waiting
Pregnancy itself can motivate individuals to reconsider tobacco and other substance use.
However, waiting for pregnancy recognition may allow exposure to continue during early development.
Preconception care creates an opportunity to address dependence and establish support before conception occurs.
This can include identifying triggers, developing a cessation plan, accessing counseling, and considering appropriate pharmacological treatment before pregnancy.
For nonpregnant adults, the USPSTF supports behavioral interventions and approved smoking-cessation medications.
Options may include nicotine replacement therapy, varenicline, or bupropion according to medical history and individual circumstances.
However, medication selection should be reviewed when pregnancy is planned.
Treatment may need to change according to the person's reproductive goals, medical conditions, and the timing of conception.
The important principle is to develop a realistic plan rather than simply recommend cessation without assistance.
11. Cannabis: A Major Change in the Preconception Landscape
Cannabis has become increasingly accessible and socially accepted in many parts of the United States.
Products are available in multiple forms, including inhaled, edible, and concentrated preparations.
Their cannabinoid concentrations can vary substantially.
This creates new challenges for preconception counseling.
Some individuals use cannabis recreationally.
Others report using it for nausea, sleep difficulties, anxiety, pain, or appetite-related concerns.
However, the perceived benefits of cannabis do not establish safety during pregnancy.
In October 2025, the American College of Obstetricians and Gynecologists published updated clinical guidance concerning cannabis use during pregnancy and lactation.
The guidance recommends screening during prepregnancy, pregnancy, and postpartum care.
It also advises cessation of cannabis use during pregnancy and lactation, while emphasizing nonjudgmental counseling and individualized support.
ACOG notes that no medical indication for cannabis use during pregnancy has been established.
12. Cannabis and Pregnancy Complications: What Large Studies Show
A 2024 study published in JAMA Internal Medicine, Prenatal Cannabis Use and Maternal Pregnancy Outcomes, examined 316,722 pregnancies.
The researchers evaluated associations between prenatal cannabis exposure and several maternal outcomes.
Cannabis use was associated with increased risk of gestational hypertension, preeclampsia, placental abruption, and gestational weight gain both above and below recommended ranges.
The study also identified a lower observed risk of gestational diabetes among cannabis-exposed pregnancies.
However, these findings require careful interpretation.
The study was observational.
Consequently, the associations do not establish that cannabis directly caused the observed outcomes.
The lower observed gestational-diabetes risk should not be interpreted as evidence that cannabis provides a protective treatment effect.
Important factors such as patterns of substance use, medical history, and other differences among participants may influence results despite statistical adjustment.
The findings nevertheless reinforce the importance of discussing cannabis during preconception care.
13. Cannabis and Child Neurodevelopment: Why the Evidence Is Complicated
Researchers continue to investigate whether prenatal cannabis exposure affects long-term neurodevelopment.
Several studies report associations involving attention, executive function, behavioral regulation, or other developmental outcomes.
However, findings are not uniform.
For example, two large studies published in JAMA Network Open in October 2024 examined early prenatal cannabis exposure.
One study evaluated autism spectrum disorder among approximately 179,000 mother–child pairs.
Another examined early developmental delays among approximately 120,000 pairs.
Neither study found a statistically significant association with the respective primary outcomes after adjustment.
These findings are relevant.
However, they do not establish that cannabis exposure is safe.
The studies evaluated particular outcomes, exposure windows, and populations.
They could not address every aspect of fetal development or long-term health.
Other investigations have identified associations with different neurobehavioral measures.
For example, a 2024 JAMA Pediatrics study found differences in selected measures of attention, inhibitory control, and observed aggression among children with prenatal cannabis exposure.
The evidence therefore remains mixed and outcome-specific.
Given the potential risks and remaining uncertainty, avoiding cannabis while planning pregnancy and during pregnancy is the more precautionary approach.
14. What Can Epigenetic Research Tell Us?
One emerging area involves the relationship between prenatal exposures and epigenetic regulation.
Epigenetic mechanisms influence gene activity without necessarily changing the underlying DNA sequence.
DNA methylation is one such mechanism.
A 2024 study published online in Molecular Psychiatry, appearing in its 2025 volume, investigated associations between prenatal cannabis exposure and DNA methylation patterns in offspring.
The researchers identified differences involving genes relevant to neurodevelopment.
These findings contribute to understanding possible biological mechanisms.
However, an epigenetic association does not prove that an exposure caused a neurological disorder.
Nor does it establish that the observed molecular changes are permanent or clinically harmful.
Epigenetic research can identify potentially relevant pathways, but clinical interpretation requires additional evidence.
This is particularly important because epigenetics is sometimes presented as if every exposure permanently reprograms future generations.
The human evidence does not support such sweeping conclusions.
15. Other Substances: Why the Type of Exposure Matters
Not all substances have the same reproductive or developmental effects.
For example, cocaine and methamphetamine are stimulant drugs associated with serious cardiovascular and other health risks.
Cocaine exposure during pregnancy has been associated with placental complications and certain adverse birth outcomes.
However, observational findings may be complicated by concurrent tobacco, alcohol, and other substance use.
Opioids represent another important category.
They may be prescribed for pain or used nonmedically.
Exposure during pregnancy requires careful evaluation of medication indication, dosage, treatment status, and other clinical factors.
Prescription medication use should not automatically be classified as substance misuse.
Similarly, someone receiving appropriate treatment for a substance use disorder should not be treated as though the treatment itself represents the same risk as uncontrolled illicit substance use.
The clinical question is not simply whether a substance is present.
It is why the substance is being used, what risks are associated with continued exposure, and what management strategy best protects the individual and prospective pregnancy.
16. Opioid Use Disorder: Why Treatment Is Essential
One of the most important advances since the original 2008 paper concerns treatment of opioid use disorder during pregnancy.
For individuals with opioid use disorder, medications such as buprenorphine and methadone are established treatments.
They can reduce risks associated with uncontrolled opioid use and support ongoing recovery.
Abruptly discontinuing treatment may increase the risk of withdrawal, recurrence of opioid use, and overdose.
A major 2022 New England Journal of Medicine study compared pregnancy outcomes among individuals receiving buprenorphine or methadone.
The study involved a large U.S. population of publicly insured pregnancies.
Among infants exposed during the 30 days before delivery, neonatal abstinence syndrome occurred in approximately 52% of the buprenorphine group and 69% of the methadone group.
Buprenorphine exposure was also associated with lower observed risks of preterm birth and low birth weight.
However, both medications remain appropriate treatment options, and their selection depends on individual clinical needs.
The study was observational and does not establish that every patient should switch from methadone to buprenorphine.
The essential message is that evidence-based addiction treatment should be maintained and coordinated appropriately—not abruptly discontinued because pregnancy is planned or recognized.
17. Why Substance-Use Screening Should Be Nonjudgmental
Screening is most useful when people feel able to discuss their circumstances openly.
However, substance-use disclosure can be influenced by fear of judgment, stigma, legal consequences, or concerns about involvement with child welfare systems.
These concerns may be especially relevant during pregnancy.
The 2025 ACOG guidance on cannabis emphasizes universal verbal screening and recommends against using biological drug testing as the routine screening method.
Toxicology tests are not equivalent to a comprehensive clinical assessment.
They may fail to identify certain exposures, detect substances long after use, or produce preliminary results requiring confirmation.
A positive result also does not independently establish a substance use disorder.
Testing may carry important social and legal consequences.
When biological testing is clinically indicated, informed consent and transparent discussion of implications are essential.
The objective of screening should be to identify opportunities for support and appropriate care.
18. Motivational Interviewing and Behavior-Change Support
Preconception substance counseling is not simply the delivery of warnings.
People may use alcohol, nicotine, or cannabis for different reasons.
Some experience physiological dependence.
Others use substances in response to stress, sleep problems, anxiety, pain, or social circumstances.
A recommendation to stop may therefore be difficult to implement without addressing the underlying factors.
Motivational interviewing is one approach used to support behavior change.
It emphasizes collaborative discussion, exploration of personal priorities, and identification of barriers.
For example, someone using cannabis for sleep may benefit from evaluating the underlying causes of sleep disturbance and discussing more appropriate treatment options.
A person who smokes cigarettes may require a structured cessation program with behavioral support.
Someone with alcohol use disorder may need specialized medical treatment.
The appropriate intervention depends on the individual's circumstances.
Health coaching may complement these efforts by helping individuals establish routines, identify triggers, and develop accountability.
However, coaching does not replace addiction treatment or medical management when indicated.
19. Preconception Health Is Also a Men's Health Issue
One important limitation of older preconception literature is its predominant focus on maternal behavior.
Contemporary research increasingly recognizes that the health of both prospective parents matters.
A 2024 review published in Nature Reviews Urology, Influence of Substance Use on Male Reproductive Health and Offspring Outcomes, examined the effects of alcohol, tobacco, cannabis, opioids, and other substances.
The authors discussed evidence linking certain exposures with sperm characteristics, endocrine function, and reproductive outcomes.
They also reviewed emerging research suggesting that paternal preconception exposures may influence offspring biology through mechanisms involving sperm and epigenetic regulation.
However, much of the mechanistic evidence comes from animal studies.
Human findings are more difficult to interpret because of confounding and challenges in measuring exposure.
It would therefore be premature to claim that paternal substance use directly causes specific childhood developmental disorders through inherited epigenetic changes.
Nevertheless, the evidence supports a broader perspective.
Preconception health should be a shared responsibility between prospective parents rather than a burden placed exclusively on women.
Both partners can benefit from reviewing substance use, medication exposures, and relevant health conditions before attempting conception.
20. Why Timing and Planning Matter
A preconception consultation creates an opportunity to assess risks before pregnancy begins.
However, there is no universal timeline that applies to every exposure.
Some substances clear from the body relatively quickly.
Others have longer elimination periods.
Physiological recovery from substance use may take longer than the disappearance of the substance itself.
For example, nicotine dependence may require weeks or months of behavioral treatment.
Recovery from alcohol or opioid use disorder may require an ongoing treatment plan.
Sperm production and maturation occur over several months, which is one reason discussions of paternal exposures often consider the preceding months.
However, the evidence does not establish one universal abstinence interval that guarantees improved reproductive or child outcomes for every substance.
A reasonable approach is to begin preconception planning early enough to assess relevant exposures, access necessary treatment, and establish sustainable changes.
When pregnancy is not yet desired, contraception counseling is also relevant.
This allows individuals to make informed decisions about pregnancy timing while addressing potentially modifiable risks.
21. Practical Steps for Prospective Parents
Preconception care should focus on actions that can meaningfully improve readiness for pregnancy.
The following considerations provide a starting point:
Review alcohol use. Individuals planning pregnancy should discuss drinking patterns and receive appropriate counseling. Avoiding alcohol while attempting conception and during pregnancy is recommended.
Address tobacco and nicotine exposure. Smoking cessation and avoidance of unnecessary nicotine exposure are important goals. Evidence-based cessation support can help.
Discuss cannabis use openly. Cannabis should not be assumed safe because it is legally available or perceived as natural. Prospective parents should discuss relevant use with healthcare professionals.
Review prescription medications. Necessary treatments should not be stopped without clinical guidance. Some medications may require adjustment before pregnancy, while others should be continued.
Seek appropriate treatment for substance use disorders. Alcohol and opioid use disorders may require specialized care. Treatment planning should prioritize safety and continuity.
Include both prospective parents. Paternal health and substance exposures may influence fertility and warrant attention.
Identify practical barriers. Stress, sleep problems, social circumstances, and dependence may complicate behavior change. Addressing these factors can support sustainable progress.
The objective is not perfection. It is informed preparation and access to appropriate support.
22. How This Research Informs Our Preconception Care
We recognize that preparing for pregnancy involves more than waiting for a positive pregnancy test.
Preconception health provides an opportunity to evaluate nutritional adequacy, lifestyle behaviors, relevant health conditions, and environmental exposures that may affect reproductive well-being.
Within our women's health and conscious conception philosophy, this includes education concerning alcohol, tobacco, nicotine, cannabis, and other substance exposures.
Our approach emphasizes understanding the individual's circumstances rather than making assumptions based on isolated behaviors.
For example, a person who uses nicotine may benefit from developing a realistic cessation plan.
Someone using alcohol to manage stress may require appropriate screening and behavioral support.
A person taking prescription medications may need to coordinate with their prescribing clinician and reproductive healthcare team.
We also recognize that the health of both prospective parents matters.
Preconception education should encourage shared participation and appropriate evaluation rather than placing the entire responsibility on the mother.
Our role is to support informed decisions, health-related behavior change, and collaboration with qualified professionals.
When specialized addiction treatment, medication management, or obstetric care is required, those services should be provided by appropriately qualified clinicians.
The objective is to help prospective parents identify meaningful opportunities for prevention while avoiding unnecessary testing, unsupported claims, or unrealistic expectations.
Conclusion: The Best Time to Begin Preparing for Pregnancy Is Before It Begins
Preconception care creates an opportunity to address factors that may influence fertility, pregnancy, and early development before those processes begin.
The original 2008 American Journal of Obstetrics & Gynecology paper helped establish alcohol, tobacco, and other substance exposures as important components of preventive reproductive healthcare.
More recent research has expanded this perspective.
We now have stronger evidence concerning certain pregnancy complications, improved understanding of developmental toxicology, and better treatment options for some substance use disorders.
We also recognize that reproductive health involves both prospective parents.
However, scientific progress requires careful interpretation.
Not every exposure causes harm.
Not every biological association establishes causation.
And discontinuing medically necessary treatment without appropriate supervision can create serious risks.
The most effective approach combines evidence-based education with individualized assessment, early intervention, and appropriate professional care.
Preconception health is not about attempting to control every biological variable. It is about identifying meaningful opportunities to reduce avoidable risks and support the health of both prospective parents before pregnancy begins.
Research References
Floyd RL, Jack BW, Cefalo R, et al. The clinical content of preconception care: alcohol, tobacco, and illicit drug exposures. American Journal of Obstetrics and Gynecology. 2008;199(6 Suppl 2)–S339. https://doi.org/10.1016/j.ajog.2008.09.018
American College of Obstetricians and Gynecologists and American Society for Reproductive Medicine. Prepregnancy counseling. Obstetrics & Gynecology. 2019. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/01/prepregnancy-counseling
US Preventive Services Task Force. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults. JAMA. 2018;320:1899–1909. https://doi.org/10.1001/jama.2018.16789
May PA, Chambers CD, Kalberg WO, et al. Prevalence of fetal alcohol spectrum disorders in 4 US communities. JAMA. 2018;319:474–482. https://doi.org/10.1001/jama.2017.21896
US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons. JAMA. 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions
Marshall AT, et al. Prenatal tobacco and alcohol exposure and cortical change among youths. JAMA Network Open. 2025. https://doi.org/10.1001/jamanetworkopen.2025.16729
Young-Wolff KC, Adams SR, Alexeeff SE, et al. Prenatal cannabis use and maternal pregnancy outcomes. JAMA Internal Medicine. 2024;184:1083–1093. https://doi.org/10.1001/jamainternmed.2024.3270
Avalos LA, Shenkute M, Alexeeff SE, et al. Maternal prenatal cannabis use and child autism spectrum disorder. JAMA Network Open. 2024;7. https://doi.org/10.1001/jamanetworkopen.2024.40301
Avalos LA, Oberman N, Alexeeff SE, et al. Early maternal prenatal cannabis use and child developmental delays. JAMA Network Open. 2024;7. https://doi.org/10.1001/jamanetworkopen.2024.40295
Noble AJ, Adams AT, Satsangi J, et al. Prenatal cannabis exposure is associated with alterations in offspring DNA methylation at genes involved in neurodevelopment, across the life course. Molecular Psychiatry. 2025;30:1418–1429. https://doi.org/10.1038/s41380-024-02752-w
Thayyil B, Yusuf K. Evidence on the effect of in-utero cannabis exposure in neonates. Journal of Perinatology. 2025;45:1503–1512. https://doi.org/10.1038/s41372-025-02383-1
American College of Obstetricians and Gynecologists. Cannabis use during pregnancy and lactation. Clinical Consensus No. 10. 2025. https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2025/10/cannabis-use-during-pregnancy-and-lactation
Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus methadone for opioid use disorder in pregnancy. New England Journal of Medicine. 2022;387:2033–2044. https://doi.org/10.1056/NEJMoa2203318
Krans EE. Neonatal outcomes after use of buprenorphine during pregnancy. New England Journal of Medicine. 2022;387:2085–2086. https://doi.org/10.1056/NEJMe2212967
Influence of substance use on male reproductive health and offspring outcomes. Nature Reviews Urology. 2024;21:534–564. https://doi.org/10.1038/s41585-024-00868-w
Lo JO, D'Mello RJ, Thompson LA. What parents need to know about maternal cannabis use during pregnancy. JAMA Pediatrics. 2026;180:1174. https://doi.org/10.1001/jamapediatrics.2026.3578